Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

SSSE:600867
7.73
CNY
+0.09
(+1.18%)
0.25EPS
28.74P/E
15.39BMarket Cap
Apr 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.69
0.81
1.01
1.22
1.49
1.32
1.37
1.43
1.6
1.39
1.55
0.96
1.5
1.63
Basic EPS, GAAP
0.11
0.16
0.3
0.38
0.49
0.41
0.4
0.46
0.64
0.79
0.59
-0.02
0.62
0.27
Free Cash Flow per Basic Share
0.02
0.06
-0.06
0.19
0.45
0.05
0.42
0.35
0.28
0.19
0.26
-0.05
0.09
- -
Dividend per Share
0.1
0.12
0.15
0.16
0.18
0.17
0.21
0.2
0.21
0.55
0.25
0.24
0.26
0.31
Book Value per Share
0.94
1.09
1.25
1.92
2.2
2.32
2.46
2.73
3.06
3.28
3.62
3.22
3.63
3.62
Tangible Book Value per Share
0.9
1.05
1.2
1.83
2.11
2.13
2.23
2.43
2.66
2.75
2.95
2.43
2.79
2.74
Basic Weighted Avg Shares
1,748
1,791
1,651
1,672
1,707
2,045
2,028
2,022
2,044
2,002
1,979
2,098
1,966
1,983
Sales/Revenue/Turnover
1,204
1,451
1,669
2,040
2,545
2,693
2,777
2,892
3,268
2,778
3,075
2,010
2,947
3,236
Operating Margin (%)
18.79
25.07
34.31
39.52
39.41
36.77
34.36
39.41
38.91
32.05
42.35
6.25
20.45
25.31
Depreciation Expense
108
113
131
160
167
172
153
155
144
151
186
189
271
- -
Net Income, GAAP
184
280
493
641
837
839
811
930
1,308
1,582
1,168
-42
1,219
542
Effective Tax Rate (%)
15.26
14.6
14.1
15.78
13.66
14.18
15
16.05
14.72
13.54
14.49
- -
18.96
23.83
Profit Margin (%)
15.27
19.28
29.53
31.41
32.87
31.14
29.21
32.15
40.03
56.93
37.97
-2.09
41.36
16.75
Working Capital
732
851
607
1,571
2,065
1,582
1,622
1,714
1,894
1,894
2,296
1,343
2,201
2,257
LT Debt
256
298
250
60
5
4
3
- -
- -
- -
- -
273
218
254
Total Equity
2,016
2,161
2,479
3,945
4,537
4,734
5,009
5,559
6,220
6,550
7,216
6,403
7,108
7,059
Return on Invested Capital (%)
7.69
11.1
16.06
16.05
19.56
17.99
16.32
18.93
22.7
25.06
17
- -
17.51
7.24
Return on Capital (%)
8.36
11.51
16.06
16.93
18.85
17.47
16.08
17.54
22.21
24.78
16.85
- -
17.09
8.17
Return on Common Equity (%)
9.31
13.55
21.45
20.03
19.76
18.13
16.68
17.62
22.23
24.8
16.98
-0.62
18.08
8.21

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
344
426
405
LT Borrowings
319
221
216
LT Finance Leases
20
34
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,959
1,959
1,959
Market Capitalization
18,587
15,747
15,394

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,061
2,628
2,963
Cash, Cash Equivalents & STI
1,805
1,383
1,634
Accounts Receivable, Net
429
429
524
Inventories
628
668
635
Total Current Liabilities
632
724
706
Payables & Accruals
- -
- -
- -
ST Debt
344
426
405
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.24%
5.42%
11.01%
Free Cash Flow
-2.59%
-79.66%
-261.22%
Net Income, GAAP
-300.16%
-614.76%
-3,005.63%
Sales/Revenue/Turnover
8.07%
4.14%
46.66%
Total Cash Common Dividend
16.33%
21.49%
-0.1%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
591
149
708
562
2,010
2025
652
722
- -
768
2,947
2026
748
805
916
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
-0.22
0.08
0.01
-0.02
2025
0.06
0.06
- -
0.01
0.62
2026
0.06
0.09
0.12
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.25
- -
- -
0.24
2025
- -
0.26
- -
- -
0.26
2026
- -
0.3
0.01
- -
- -

Company Description

CEO
Jia Hong Li
Full Time Employees
3,354
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Dongbao New Village Tonghua JI China 134123
IPO Date
Aug 24, 1994
Website
thdb.com
Business
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) manufactures and markets pharmaceuticals with a focus on diabetes treatments, including recombinant human insulin (Gansulin), insulin glargine (Pingsulin), insulin aspart (Ruisulin), insulin aspart mix 70/30 and 50/50, liraglutide injections (Tongboli), oral antidiabetics such as repaglinide tablets (Tangjierui), empagliflozin tablets (Tangjieen), sitagliptin phosphate tablets and combinations; Chinese patent medicines like Zhennaoning capsules for vascular neuropathic headache and Dongbao Gantai tablets for fatty liver; gout therapies including novel URAT1 inhibitors (THDBH130) and dual-target XO/URAT1 inhibitors (THDBH151); diabetes-related devices such as insulin pens, needles, blood glucose monitors, and patient management systems; founded in 1985 and headquartered in Tonghua, Jilin Province, China. The company operates primarily in China through subsidiaries like Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. for R&D and Tonghua Dongbao Group Import & Export Co., Ltd. for international trade, with expansion into Southeast Asia, Middle East, East Asia, South America, Africa, EU filings for insulins, and US market partnerships; it listed on the Shanghai Stock Exchange in 1994 and maintains production sites including a Biopharmaceutical Industrial Park with capacity exceeding 300 million cartridges and vials annually. Recent developments encompass Phase III initiation of semaglutide injections (THDB0225) in July 2024 via licensing with Beijing Quality Peptide Biopharmaceutical Technology Co., Ltd.; strategic cooperation with Sinopharm Group Co., Ltd. in June 2024; EMA certification of human insulin drug substance facilities for EU commercial manufacturing in July 2024 following April inspection; Category A/A1 selection for all insulin products in China's April 2024 volume-based procurement through 2027; multiple 2024 clinical milestones including Phase Ib trials for GLP-1/GIP agonist THDBH120 in diabetes and weight loss, Phase IIa for gout dual inhibitor THDBH151, Phase I completion for insulin degludec/liraglutide combination; ongoing share repurchases totaling over 3% of shares by November 2025 under plans authorized October 2025 and earlier; leadership changes appointing Li Jiahong as Chairman and Leng Chunsheng as Vice Chairman/General Manager in March 2024; Jilin Province funding for insulin degludec technology in January 2024.